Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Wednesday January 11, 2017 at the Biotech Showcase 9th Annual Conference at the Hilton San Francisco Union Square, 333 O'Farrell St, San Francisco. The conference takes place between Jan. 9-11, 2017.
Staffan Strömberg, President and Chief Executive Officer will represent the company in the presentation scheduled to begin at 11:30 am Pacific Time.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme for the unmet medical need Gastroschisis-Related Intestinal Dysfunction ("GRID"), a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.
IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.
For additional information please contact
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 8 410 145 55
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infant Bacterial Therapeutics AB via Globenewswire